Theraclion names Vincent Gardès as board chairman
- Investing.com
Metrics to compare | ALTHER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALTHERPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.4x | −1.3x | −0.2x | |
PEG Ratio | - | 0.00 | 0.00 | |
Price/Book | −16.8x | 1.0x | 2.6x | |
Price / LTM Sales | 90.5x | 0.8x | 2.8x | |
Upside (Analyst Target) | 241.8% | 122.2% | 65.0% | |
Fair Value Upside | Unlock | 19.1% | 9.5% | Unlock |
Theraclion SA provides therapeutic ultrasound technology for seamless vein care. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient’s skin and optimize image quality. The company was incorporated in 2004 and is headquartered in Malakoff, France.